Catalent Pharma Solutions Enters Into Commercial Supply Agreement With VIVUS, Inc. (VVUS) for Qsymia Once-Daily Combination-Extended-Release Capsules
10/1/2012 10:16:36 AM
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent Pharma Solutions announced that it has entered into a Supply Agreement with VIVUS, Inc. to supply Qsymia™ capsules, a proprietary combination phentermine and extended-release topiramate. Utilizing its unique drug delivery capabilities, Catalent partnered with VIVUS during the development of Qsymia, including pre-formulation and formulation, clinical supply and validation.
comments powered by